The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 6% in the afternoon. As of press release, it had risen 4.24% to HK$11.3, with a turnover of HK$14.146,600.

According to the news, Junshi Biotech announced its results for the first quarter of 2024, with operating income of about 381 million yuan, an increase of 49.24%; net loss attributable to shareholders of listed companies was about 283 million yuan, a year-on-year narrowing of 47.92%; and a basic loss of 0.29 yuan per share.

During the reporting period, the company's revenue growth was mainly due to an increase in sales revenue of commercial pharmaceuticals. Among them, the core product treprilizumab injection (product name: Tuoyi/LOQTORZI, product code: JS001) achieved sales revenue of about 307 million yuan in the domestic market, an increase of about 56.82% over the previous year. At the same time, during the reporting period, the company continued to strengthen cost control, optimize resource allocation, and focus on more promising R&D pipelines. Losses decreased compared with the same period last year.